Back
27 February 2026
The ITA, on behalf of the IWF, confirms that the athlete Neisi Patricia Dajomes Barrera has agreed¹ to the consequences imposed for her anti-doping rule violation (ADRV).
The athlete tested positive for the prohibited substance clomifene after providing an out-of-competition sample on 7 April 2025.
Clomifene is prohibited under the WADA Prohibited List as S4.2. Anti-Estrogenic Substances. It is prohibited at all times (in- and out-of-competition) and is classified as a specified substance.
The athlete did not challenge her ADRV and agreed with the consequences that apply, namely a period of ineligibility of fourteen months from 2 June 2025 until 1 August 2026 and disqualification of competitive results from 7 April 2025 onwards.
The relevant stakeholders, namely the World Anti-Doping Agency and the National Anti-Doping Unit of Ecuador, have a right to appeal the consequences imposed before the appeals division of the Court of Arbitration for Sport.
The ITA will not comment further on this case.
¹ Athletes have the right to choose not to have their case referred to a hearing panel. In these instances, the anti-doping organisation will assess the athlete’s case file and establish the applicable consequences pursuant to the anti-doping rules and the athlete will have the right to accept the proposed consequences. If the athlete refuses the proposed consequences, the case is transferred to a hearing panel. This resolution mechanism is provided for in articles 8.3.1 and 8.3.3 of the IWF anti-doping rules and 8.3 of the World Anti-Doping Code and is commonly referred to as an agreement on consequences and is deemed an IWF/ITA decision. The athlete’s National Anti-Doping Organisation and the World Anti-Doping Agency have the right to appeal the agreement on consequences before the competent appeal body.
